VivoSim Labs, INC. 8-K

What Happened
VivoSim Labs, Inc. (VIVS) filed an 8-K disclosing that on July 16, 2026 it entered a Securities Purchase Agreement for a private placement with an accredited institutional investor. The deal will issue pre‑funded warrants and accompanying common stock purchase warrants covering up to 4,705,883 shares each, at a combined purchase price of $0.85 per share/unit, for gross proceeds of approximately $4.0 million (before placement agent fees and expenses). The closing is expected on or about July 17, 2026. The company said proceeds will be used for working capital and general corporate purposes.

Key Details

• Private placement size: ~4,705,883 pre‑funded warrants and 4,705,883 common warrants; combined purchase price = $0.85 per share/unit; gross proceeds ≈ $4.0M (before fees).
• Pre‑Funded Warrant terms: $0.001 exercise price; exercisable immediately; cash or cashless exercise; expires when fully exercised.
• Common Warrant terms: $0.85 exercise price; exercisable only after company obtains shareholder approval and for five years thereafter; cash exercise generally, cashless if the underlying shares are not immediately resalable.
• Ownership caps: exercises limited so holder (with affiliates) cannot exceed 9.99% (pre‑funded) or 4.99% (common) of outstanding shares immediately after exercise (holder may adjust this percentage with notice, up to 9.99%).
• Placement agent: A.G.P./Alliance Global Partners; fee = 6.50% of gross proceeds.
• Armistice amendment: the company amended prior warrants issued to Armistice Capital Master Fund Ltd. to set exercise price at $0.85 and extend expiration to five years after shareholder approval.
• Company agreed to customary closing conditions, indemnities and a limited lock‑up on issuing additional equity until 60 days after effectiveness of a registration statement covering resale of the warrant shares.

Why It Matters
This transaction provides VivoSim with near‑term capital (about $4M) to support operations and general purposes, which can be important for a small biotech or development-stage company. However, the issuance of a large number of warrants creates potential future dilution if and when those warrants are exercised. The common warrants require shareholder approval before exercise becomes effective, which could delay or affect when additional shares enter the market. Investors should watch for the closing, the filing/ effectiveness of the registration statement for the warrant shares, and any shareholder votes related to warrant approvals.